An assessment by the Statin cognitive safety task force: 2014 update

Carlos H. Rojas-Fernandez, Larry B. Goldstein, Allan I. Levey, Beth A. Taylor, Vera Bittner

Research output: Contribution to journalArticlepeer-review

84 Scopus citations


The National Lipid Association's Safety Task Force convened a consensus conference of experts to develop a position statement on cognitive function to revise and update that published originally by the Association in the 2006 assessment of statin safety by a panel of neurologists. The current expert panel was charged with addressing the specific issue of potential adverse cognitive effects attributable to statins. Search strategies recently used in systematic reviews were used to identify relevant evidence using keywords and topics via Medline searches from 1966 to December 2013. Manual searches of bibliographies were also conducted. Panel members were asked to use the evidence to formulate answers to a series of questions of relevance to the subject matter. The strength of recommendations and quality of evidence were graded using accepted contemporary definitions and procedures. Recommendations to patients, health professionals, and researchers were put forth by the panel to aid in daily clinical decision making, and in future research endeavors.

Original languageEnglish
Pages (from-to)S5-S16
JournalJournal of Clinical Lipidology
Issue number3 SUPPL
StatePublished - 2014

Bibliographical note

Funding Information:
Disclosures: The authors disclose that they have the following relationships with industry that might pose a potential conflict of interest(s): Dr Carlos Rojas-Fernandez (research grant support from Astra Zeneca, Pfizer, Bristol Myers Squibb, Medisystems Pharmacy, and Remedy's Rx Pharmacies ); Dr Allan Levey (research grant support from NIH [ P50 AG025688 ], Merck, Eli Lilly, Lundbeck, and Neurovision ; and consultant for Genomind and Genentech); Dr Larry Goldstein (past consultant for Pfizer and speaker at Pfizer-sponsored meetings); Dr Beth Taylor (honoraria - Pharmacovigilance Advisory Board Amgen, Inc.); and Dr Vera Bittner (research support from Amgen, Bayer Healthcare, Glaxo-Smith-Kline, Pfizer, Roche, and Sanofi Aventis ; and consultant for Amarin, Novartis, and the Federal Drug Administration).


  • Adverse drug effects
  • Cognition
  • Iatrogenesis
  • Memory
  • Statins

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'An assessment by the Statin cognitive safety task force: 2014 update'. Together they form a unique fingerprint.

Cite this